Typhoid vaccine for infants 'safe': study

Vaccine
Credit: National Cancer Institute
A trial vaccine against typhoid, a disease that kills more than 200,000 people every year, is safe for use, researchers said on Friday.

Aimed at children under two, who are disproportionately affected, the vaccine may prevent more than half of all typhoid infections, they wrote in The Lancet medical journal.

Dubbed Vi-TT, the vaccine studied in the trial is already licensed for use in infants in India, but nowhere else, nor are there any other vaccines for children under two.

Typhoid is caused by an infection with the bacteria Salmonella Typhi, usually through , particularly in parts of south Asia and sub-Saharan Africa with inadequate sanitation.

About one in 100 cases are deadly.

According to the World Heath Organization, typhoid affects about 21 million people per year, and kills around 222,000.

Symptoms include fever, headache, nausea, loss of appetite, constipation and sometimes diarrhoea.

The vaccine was tested on adult volunteers in Britain, who were given a dose of bacteria. Those who fell ill were treated with antibiotics.

Symptoms were "less severe" in people given the trial vaccine, who also had lower bacterial numbers in their blood, the team found. Those not given Vi-TT received other existing vaccines to enable researchers to compare the results.

The trial, funded by the Bill & Melinda Gates Foundation and the European Commission, continues.


Explore further

Anti-typhoid gene found, may improve vaccines

Journal information: The Lancet

© 2017 AFP

Citation: Typhoid vaccine for infants 'safe': study (2017, September 29) retrieved 20 September 2019 from https://medicalxpress.com/news/2017-09-typhoid-vaccine-infants-safe.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.
3 shares

Feedback to editors

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more